drugset / Trial / NCT03638466

Exploratory fMRI Study on the Treatment for Impulsive Aggression in Children With ADHD

NCT03638466

Phase 2 Terminated 7 enrolled Supernus Pharmaceuticals, Inc.
RandomizedParallel-groupQuadruple-blindBasic science

Summary

The purpose of this study was to evaluate the effect of 4-week SPN-810 treatment on brain functioning in patients aged 8-12 years with ADHD and associated feature of impulsive aggression (IA). This was achieved using functional magnetic resonance imaging (fMRI) in conjunction with the point subtraction aggression paradigm (PSAP) Task, a behavioral aggression paradigm in which subjects are provoked by having money indirectly taken from them by a fictitious opponent, simulating an aggression response.

Timeline

Start
2019-05-30
Primary completion
2019-11-07
Completion
2019-11-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Molindone Small molecule 18 mg